7-溴-4,4-二甲基-3,4-二氢-1H-喹啉-2-酮 | 185316-44-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 7-溴-4,4-二甲基-3,4-二氢-1H-喹啉-2-酮
• 中文别名: 7-溴-4,4-二甲基-3,4-二氢-2-喹啉酮
• 英文名称: 7-bromo-4,4-dimethyl-3,4-dihydroquinolin-2(1H)-one
• 英文别名: 7-bromo-4,4-dimethyl-1,3-dihydroquinolin-2-one
• CAS: 185316-44-3
• 化学式: C₁₁H₁₂BrNO
• 分子量: 254.126
• InChiKey: XNONCRQWDVQJRP-UHFFFAOYSA-N

物化性质

• 沸点：
  352.5±42.0 °C(Predicted)
• 密度：
  1.385±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933790090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 7-Bromo-4,4-dimethyl-1,3-dihydroquinolin-2-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 7-Bromo-4,4-dimethyl-1,3-dihydroquinolin-2-one
CAS number: 185316-44-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H12BrNO
Molecular weight: 254.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-溴-4,4-二甲基-3,4-二氢-1H-喹啉-2-酮 在 硼烷四氢呋喃络合物 作用下， 以 甲苯 为溶剂， 反应 4.0h， 以90%的产率得到7-溴-4,4-二甲基-1,2,3,4-四氢-喹啉
  参考文献：
  名称：

  靶向髓系白血病中 STAT5 信号传导的抑制剂：具有改善抗白血病潜力的新型四氢喹啉衍生物

  摘要：

  信号转导和转录激活因子 5A 和 5B（STAT5A 和 STAT5B）是两个密切相关的 STAT 家族成员，它们是酪氨酸激酶癌蛋白（如急性髓性白血病 (AML) 中的 FLT3-ITD 和慢性髓性白血病中的 BCR-ABL）的关键下游效应器(CML)。我们最近开发并报告了第一个称为17 f 的分子的合成，该分子选择性地抑制髓系白血病细胞中的 STAT5 信号传导并克服它们对化学治疗剂的抗性。为了提高17 f的抗白血病作用，我们合成了该分子的十种类似物，并分析了它们对细胞生长、存活、化学抗性和 STAT5 信号传导的影响。两种化合物，7 a和7 a', 被确定为在各种 AML 和 CML 细胞系中具有相似或更高的抗白血病作用。发现这两种分子在抑制 STAT5 活性/表达和抑制 CML 的化学抗性方面比17 f更有效。

  DOI：

  10.1002/cmdc.202000841
• 作为产物：
  描述：

  N-(3-bromophenyl)-3-methylbut-2-enamide 在 AlCl₃ 作用下， 以 二氯甲烷 为溶剂， 生成 7-溴-4,4-二甲基-3,4-二氢-1H-喹啉-2-酮
  参考文献：
  名称：

  Acetylenes disubstituted with a phenyl or heteroaryl group and a

  摘要：

  式子为 ##STR1## 的化合物，其中符号的定义如规范所述。

  公开号：

  US05616712A1

文献信息

• Syk 억제제
  申请人：GILEAD SCIENCES, INC. 길리애드 사이언시즈, 인코포레이티드(519990290219)

  公开号：KR20160037198A

  公开（公告）日：2016-04-05

  본 개시내용은 Syk 억제제인 화합물, 및 암 및 염증성 상태를 비롯한 다양한 질환 상태의 치료에서의 그의 용도에 관한 것이다. 특정한 실시양태에서, 화합물의 구조는 하기 화학식 I로 주어진다. 003c#화학식 I003e# 상기 식에서, X, X, X, R, R, R, R, 및 Y는 본원에 기재된 바와 같다. 본 개시내용은 화학식 I의 화합물 또는 그의 제약상 허용되는 염을 포함하는 제약 조성물, 및 Syk에 의해 매개되는 상태를 치료하기 위해 이들 화합물 및 조성물을 사용하는 방법을 추가로 제공한다.

  This text appears to be a scientific or technical document discussing the therapeutic uses of a compound called Syk inhibitor in the treatment of various conditions including cancer and inflammatory diseases. It also mentions the chemical structure of the compound given by the chemical formula I. In the formula, X, X, X, R, R, R, R, and Y are as described in the specification. The document further provides methods for using these compounds and compositions containing compounds or salts thereof of the chemical formula I to treat conditions mediated by Syk.
• SYK INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150038488A1

  公开（公告）日：2015-02-05

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I wherein X 1 , X 2 , X 3 , R 2 , R 3 , R 4 , R 5 , and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及的化合物是Syk抑制剂，并且适用于治疗各种疾病状态，包括癌症和炎症性疾病。在特定实施例中，化合物的结构由公式I给出，其中X1、X2、X3、R2、R3、R4、R5和Y如本文所述。本公开进一步提供了包括公式I的化合物或其药学上可接受的盐的制药组合物，以及使用这些化合物和组合物治疗Syk介导的疾病的方法。
• Substituted pyrrolidines as SYK inhibitors
  申请人：Gilead Sciences, Inc.

  公开号：US09376441B2

  公开（公告）日：2016-06-28

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及的化合物是Syk抑制剂，用于治疗各种疾病状态，包括癌症和炎症疾病。在特定实施例中，化合物的结构由公式I给出：其中X1、X2、X3、R2、R3、R4、R5和Y如本文所述。本公开还提供了含有公式I的化合物或其药学上可接受的盐的药物组合物，以及使用这些化合物和组合物治疗由Syk介导的疾病状态的方法。
• Syk inhibitors
  申请人：Gilead Sciences, Inc.

  公开号：US10005774B2

  公开（公告）日：2018-06-26

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及作为 Syk 抑制剂的化合物及其在治疗各种疾病（包括癌症和炎症）中的用途。在特定的实施方案中，化合物的结构如式 I 所示： 其中 X1、X2、X3、R2、R3、R4、R5 和 Y 如本文所述。本公开进一步提供了包括式 I 的化合物或其药学上可接受的盐的药物组合物，以及使用这些化合物和组合物治疗由 Syk 介导的病症的方法。
• Synthesis and biological activity of 1,2,3,4-tetrahydroquinoline and 3,4-(1H)-dihydroquinolin-2-one analogs of retinoic acid
  作者：Richard L. Beard、Min Teng、Diana F. Colon、Tien T. Duong、Scott M. Thacher、Taghreed Arefieg、Roshantha A.S. Chandraratna

  DOI：10.1016/s0960-894x(97)00435-6

  日期：1997.9

  Retinoids are natural and synthetic analogs of the hormone retinoic acid. Retinoids are currently being investigated clinically as drugs in several areas, including dermatology and oncology. We report the synthesis and biological activity of a new series of potent, RAR-specific retinoids substituted with a 1,2,3,4-tetrahydroquinoline or a 3,4-(1H)-dihydroquinolin-2-one group. (C) 1997 Elsevier Science Ltd.